Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Infusions of regulatory T cells turn off autoimmune attack on joints

Infusions of regulatory T cells turn off autoimmune attack on joints

Tofacitinib fights rheumatoid arthritis progression

Tofacitinib fights rheumatoid arthritis progression

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

Eisai announces FDA acceptance of AcipHex NDA for priority review

Eisai announces FDA acceptance of AcipHex NDA for priority review

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Two equally effective TNF inhibitors in rheumatoid arthritis

Two equally effective TNF inhibitors in rheumatoid arthritis

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Gene variant predicts lymphoma treatment response

Gene variant predicts lymphoma treatment response

Preeclampsia risk higher for women with Lupus

Preeclampsia risk higher for women with Lupus

Carotid ultrasound improves risk management in rheumatoid arthritis

Carotid ultrasound improves risk management in rheumatoid arthritis

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Early, intensive therapy with adalimumab can help treat rheumatoid arthritis

Early, intensive therapy with adalimumab can help treat rheumatoid arthritis

Positive results from Antares Pharma’s VIBEX MTX clinical study on rheumatoid arthritis

Positive results from Antares Pharma’s VIBEX MTX clinical study on rheumatoid arthritis